Prognostic value of lncRNA HOXA‐AS3 in cervical cancer by targeting miR ‐29a‐3p and its regulatory effect on tumor progression

Le résumé fourni par la source

BACKGROUND: With the promotion of human papillomavirus (HPV) vaccine, cervical cancer has become a current research hotspot, and lncRNA has been confirmed to be used in the research of different diseases. This article systematically expounds the regulation and potential mechanisms of HOXA cluster antisense RNA 3 (HOXA-AS3) in cervical cancer, and discusses its possibility as a prognostic biomarker for cervical cancer. METHODS: Relative expression levels of HOXA-AS3 and miR-29a-3p in tissues and cells were determined by real-time quantitative polymerase chain reaction (RT-qPCR). The survival of cervical cancer patients was analyzed by Kaplan-Meier method and the cumulative survival function table was drawn. The proliferation, migration, and invasion levels of HOXA-AS3 in cells were detected according to cell counting kit-8 (CCK-8) and transwell method. The dual-luciferase reporter gene assay confirmed the mechanism of action between HOXA-AS3 and miR-29a-3p. RESULTS: HOXA-AS3 was elevated and miR-29a-3p was decreased in tissues and cells of cervical cancer patients. Knockdown of HOXA-AS3 could inhibit the progression of cervical cancer and was more conducive to patient survival. Bioinformatics analysis confirmed that HOXA-AS3 negatively regulates cervical cancer development by sponging miR-29a-3p. CONCLUSION: In this research, knockdown of HOXA-AS3 could alleviate the process of cervical cancer by sponging miR-29a-3p, suggesting that HOXA-AS3 may be a potential prognostic target of cervical cancer, which could provide a theoretical basis for future clinical research of cervical cancer.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.